Loading
Upgraded CAR-T cells that also secrete immune boosters, resist exhaustion, or only fire when two signals are present.
Armoured and logic-gated CARs add transgenes or synthetic circuits that change how CAR-T cells behave in the tumour microenvironment: IL-12 or IL-18 secretion, dominant-negative TGF-β receptors, PD-1 knockout, synNotch logic gates (AND/NOT gating for solid tumours, for example Arsenal Bio), and tunable CARs. Each design addresses one of the solid-tumour barriers of exhaustion, immune suppression, or on-target off-tumour toxicity, with logic gating meant to fire only when two antigens are present together. These constructs are designed for hostile solid-tumour environments where first-generation CARs failed. The cost is complexity, and the safety of constitutively secreted cytokines is unresolved, so most programmes are phase 1. The simple version is an upgraded CAR-T that carries its own boosters, armour, or a two-signal safety switch.
Additional transgenes or synthetic circuits modify CAR-T behaviour in the tumour microenvironment.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Query for this technology: (TITLE:"armored CAR T" OR ABSTRACT:"armored CAR T" OR TITLE:"armoured CAR T" OR ABSTRACT:"armoured CAR T" OR TITLE:"logic-gated CAR" OR ABSTRACT:"logic-gated CAR" OR TITLE:"synNotch CAR" OR ABSTRACT:"synNotch CAR"). Results are unfiltered search hits about Armoured, logic-gated & next-gen CARs, not a curated reading list.
Shares Logic-gated therapeutics (AND, NOT gates), Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR, CAR-T cell therapy, Glioma & glioblastoma and the tag frontier.
Shares Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer, Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR, CAR-T cell therapy and the tag frontier.
Shares Nutrient competition & metabolic immunosuppression, Mesothelioma and the tag frontier.
Shares Logic-gated therapeutics (AND, NOT gates) and the tag frontier.
Shares Nutrient competition & metabolic immunosuppression and the tag frontier.
Shares Logic-gated therapeutics (AND, NOT gates) and the tag frontier.
Shares Glioma & glioblastoma and the tag frontier.
Shares CAR-T cell therapy and the tag frontier.